Plain-English translation of NCT06982469 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Prostate Cancer research guide →This trial is testing a combination treatment for prostate cancer that has returned in the area where the prostate was surgically removed. The treatment combines two types of radiation: high-dose rate brachytherapy (a specialized procedure where radiation is placed directly into the tumor area) and external beam radiation (similar to standard radiation therapy). The goal is to deliver higher doses of radiation to the cancer while protecting nearby healthy tissues.
Some patients experience prostate cancer recurrence in the surgical bed after their prostate is removed, even though initial treatment was completed. This trial exists to test whether this newer combination approach can better target the recurrent cancer while sparing important nearby structures that control urination and sexual function.
You likely qualify if…
You likely don't qualify if…
You would receive a combination of treatments over several months. First, you would have a specialized brachytherapy procedure where radiation is placed directly into the recurrent tumor area using ultrasound guidance. This would be combined with external beam radiation therapy (similar to standard radiation) and hormonal therapy for 6 months. You would need imaging scans to plan the treatment and follow-up visits to monitor your response and any side effects.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
Spain